Loading…
Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men
Glitazones are used in the treatment of type 2 diabetes as efficient insulin sensitizers. They can, however, induce peripheral edema through an unknown mechanism in up to 18% of cases. In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of a 6-wk...
Saved in:
Published in: | The journal of clinical endocrinology and metabolism 2004-03, Vol.89 (3), p.1140-1145 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763 |
---|---|
cites | cdi_FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763 |
container_end_page | 1145 |
container_issue | 3 |
container_start_page | 1140 |
container_title | The journal of clinical endocrinology and metabolism |
container_volume | 89 |
creator | Zanchi, Anne Chiolero, Arnaud Maillard, Marc Nussberger, Jürg Brunner, Hans-Rudolf Burnier, Michel |
description | Glitazones are used in the treatment of type 2 diabetes as efficient insulin sensitizers. They can, however, induce peripheral edema through an unknown mechanism in up to 18% of cases. In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of a 6-wk administration of pioglitazone (45 mg daily) or placebo on the blood pressure, hormonal, and renal hemodynamic and tubular responses to a low (LS) and a high (HS) sodium diet in healthy volunteers. Pioglitazone had no effect on the systemic and renal hemodynamic responses to salt, except for an increase in daytime heart rate. Urinary sodium excretion and lithium clearance were lower with pioglitazone, particularly with the LS diet (P < 0.05), suggesting increased sodium reabsorption at the proximal tubule. Pioglitazone significantly increased plasma renin activity with the LS (P = 0.02) and HS (P = 0.03) diets. Similar trends were observed with aldosterone. Atrial natriuretic levels did not change with pioglitazone. Body weight increased with pioglitazone in most subjects. Pioglitazone stimulates plasma renin activity and favors sodium retention and weight gain in healthy volunteers. These effects could contribute to the development of edema in some subjects treated with glitazones. |
doi_str_mv | 10.1210/jc.2003-031526 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71718739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71718739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763</originalsourceid><addsrcrecordid>eNp1kcGOUyEUhonROJ3q1qVho7tb4QKXy7KZjNZkjM2oiTtCuYcp9RYqUGfGN_B5fA-fSWqb6EYSwjnw_efAD0LPKJnRlpJXGztrCWENYVS03QM0oYqLRlIlH6IJIS1tlGw_n6HznDeEUM4Fe4zOqKixUGqCflw6B7ZkHB0ua8BLSPHO57g1I16mOHoHyZSYmrkt_pspMOBrsLA7bP36iec3Mfhc8NLHm9EX8z0GwDFUJtQCJgx4EdM2HpJryLsYMmRcIv5gxoJ9wAuowfoev4PwBD1yZszw9LRO0afXlx8vFs3V-zdvL-ZXjeWi7RvGhCKWrZTqJacrUJwyKZgTTIieGSm569tB2tWqM60cBt47cB2lQ6d4Pe3YFL081t2l-HUPueitzxbG0QSI-6wllbSXTFVwdgRtijkncHqX_Nake02JPpivN1YfzNdH86vg-anyfrWF4S9-crsCL06AydaMLplgff6HE0zR-pgp4kfuNo4FUv4y7m8h6fUfszSpg3eyb2pvTljNmjppX2XiKIMwRJt8gF2CnPUm7lP9gfy_e_8GTn2u-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71718739</pqid></control><display><type>article</type><title>Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men</title><source>Oxford Journals Online</source><creator>Zanchi, Anne ; Chiolero, Arnaud ; Maillard, Marc ; Nussberger, Jürg ; Brunner, Hans-Rudolf ; Burnier, Michel</creator><creatorcontrib>Zanchi, Anne ; Chiolero, Arnaud ; Maillard, Marc ; Nussberger, Jürg ; Brunner, Hans-Rudolf ; Burnier, Michel</creatorcontrib><description>Glitazones are used in the treatment of type 2 diabetes as efficient insulin sensitizers. They can, however, induce peripheral edema through an unknown mechanism in up to 18% of cases. In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of a 6-wk administration of pioglitazone (45 mg daily) or placebo on the blood pressure, hormonal, and renal hemodynamic and tubular responses to a low (LS) and a high (HS) sodium diet in healthy volunteers. Pioglitazone had no effect on the systemic and renal hemodynamic responses to salt, except for an increase in daytime heart rate. Urinary sodium excretion and lithium clearance were lower with pioglitazone, particularly with the LS diet (P < 0.05), suggesting increased sodium reabsorption at the proximal tubule. Pioglitazone significantly increased plasma renin activity with the LS (P = 0.02) and HS (P = 0.03) diets. Similar trends were observed with aldosterone. Atrial natriuretic levels did not change with pioglitazone. Body weight increased with pioglitazone in most subjects. Pioglitazone stimulates plasma renin activity and favors sodium retention and weight gain in healthy volunteers. These effects could contribute to the development of edema in some subjects treated with glitazones.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2003-031526</identifier><identifier>PMID: 15001599</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Aldosterone - blood ; Atrial Natriuretic Factor - blood ; Biological and medical sciences ; Blood Pressure - drug effects ; Cross-Over Studies ; Diet, Sodium-Restricted ; Endocrinopathies ; Fundamental and applied biological sciences. Psychology ; Humans ; Hypoglycemic Agents - administration & dosage ; Male ; Medical sciences ; Placebos ; Receptors, Cytoplasmic and Nuclear - agonists ; Renal Circulation - drug effects ; Renin - blood ; Sodium Chloride - pharmacokinetics ; Sodium Chloride - urine ; Thiazolidinediones - administration & dosage ; Transcription Factors - agonists ; Vertebrates: endocrinology</subject><ispartof>The journal of clinical endocrinology and metabolism, 2004-03, Vol.89 (3), p.1140-1145</ispartof><rights>Copyright © 2004 by The Endocrine Society</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763</citedby><cites>FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15539175$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15001599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zanchi, Anne</creatorcontrib><creatorcontrib>Chiolero, Arnaud</creatorcontrib><creatorcontrib>Maillard, Marc</creatorcontrib><creatorcontrib>Nussberger, Jürg</creatorcontrib><creatorcontrib>Brunner, Hans-Rudolf</creatorcontrib><creatorcontrib>Burnier, Michel</creatorcontrib><title>Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Glitazones are used in the treatment of type 2 diabetes as efficient insulin sensitizers. They can, however, induce peripheral edema through an unknown mechanism in up to 18% of cases. In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of a 6-wk administration of pioglitazone (45 mg daily) or placebo on the blood pressure, hormonal, and renal hemodynamic and tubular responses to a low (LS) and a high (HS) sodium diet in healthy volunteers. Pioglitazone had no effect on the systemic and renal hemodynamic responses to salt, except for an increase in daytime heart rate. Urinary sodium excretion and lithium clearance were lower with pioglitazone, particularly with the LS diet (P < 0.05), suggesting increased sodium reabsorption at the proximal tubule. Pioglitazone significantly increased plasma renin activity with the LS (P = 0.02) and HS (P = 0.03) diets. Similar trends were observed with aldosterone. Atrial natriuretic levels did not change with pioglitazone. Body weight increased with pioglitazone in most subjects. Pioglitazone stimulates plasma renin activity and favors sodium retention and weight gain in healthy volunteers. These effects could contribute to the development of edema in some subjects treated with glitazones.</description><subject>Adult</subject><subject>Aldosterone - blood</subject><subject>Atrial Natriuretic Factor - blood</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cross-Over Studies</subject><subject>Diet, Sodium-Restricted</subject><subject>Endocrinopathies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Placebos</subject><subject>Receptors, Cytoplasmic and Nuclear - agonists</subject><subject>Renal Circulation - drug effects</subject><subject>Renin - blood</subject><subject>Sodium Chloride - pharmacokinetics</subject><subject>Sodium Chloride - urine</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Transcription Factors - agonists</subject><subject>Vertebrates: endocrinology</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp1kcGOUyEUhonROJ3q1qVho7tb4QKXy7KZjNZkjM2oiTtCuYcp9RYqUGfGN_B5fA-fSWqb6EYSwjnw_efAD0LPKJnRlpJXGztrCWENYVS03QM0oYqLRlIlH6IJIS1tlGw_n6HznDeEUM4Fe4zOqKixUGqCflw6B7ZkHB0ua8BLSPHO57g1I16mOHoHyZSYmrkt_pspMOBrsLA7bP36iec3Mfhc8NLHm9EX8z0GwDFUJtQCJgx4EdM2HpJryLsYMmRcIv5gxoJ9wAuowfoev4PwBD1yZszw9LRO0afXlx8vFs3V-zdvL-ZXjeWi7RvGhCKWrZTqJacrUJwyKZgTTIieGSm569tB2tWqM60cBt47cB2lQ6d4Pe3YFL081t2l-HUPueitzxbG0QSI-6wllbSXTFVwdgRtijkncHqX_Nake02JPpivN1YfzNdH86vg-anyfrWF4S9-crsCL06AydaMLplgff6HE0zR-pgp4kfuNo4FUv4y7m8h6fUfszSpg3eyb2pvTljNmjppX2XiKIMwRJt8gF2CnPUm7lP9gfy_e_8GTn2u-w</recordid><startdate>200403</startdate><enddate>200403</enddate><creator>Zanchi, Anne</creator><creator>Chiolero, Arnaud</creator><creator>Maillard, Marc</creator><creator>Nussberger, Jürg</creator><creator>Brunner, Hans-Rudolf</creator><creator>Burnier, Michel</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200403</creationdate><title>Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men</title><author>Zanchi, Anne ; Chiolero, Arnaud ; Maillard, Marc ; Nussberger, Jürg ; Brunner, Hans-Rudolf ; Burnier, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aldosterone - blood</topic><topic>Atrial Natriuretic Factor - blood</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cross-Over Studies</topic><topic>Diet, Sodium-Restricted</topic><topic>Endocrinopathies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Placebos</topic><topic>Receptors, Cytoplasmic and Nuclear - agonists</topic><topic>Renal Circulation - drug effects</topic><topic>Renin - blood</topic><topic>Sodium Chloride - pharmacokinetics</topic><topic>Sodium Chloride - urine</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Transcription Factors - agonists</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zanchi, Anne</creatorcontrib><creatorcontrib>Chiolero, Arnaud</creatorcontrib><creatorcontrib>Maillard, Marc</creatorcontrib><creatorcontrib>Nussberger, Jürg</creatorcontrib><creatorcontrib>Brunner, Hans-Rudolf</creatorcontrib><creatorcontrib>Burnier, Michel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zanchi, Anne</au><au>Chiolero, Arnaud</au><au>Maillard, Marc</au><au>Nussberger, Jürg</au><au>Brunner, Hans-Rudolf</au><au>Burnier, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2004-03</date><risdate>2004</risdate><volume>89</volume><issue>3</issue><spage>1140</spage><epage>1145</epage><pages>1140-1145</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Glitazones are used in the treatment of type 2 diabetes as efficient insulin sensitizers. They can, however, induce peripheral edema through an unknown mechanism in up to 18% of cases. In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of a 6-wk administration of pioglitazone (45 mg daily) or placebo on the blood pressure, hormonal, and renal hemodynamic and tubular responses to a low (LS) and a high (HS) sodium diet in healthy volunteers. Pioglitazone had no effect on the systemic and renal hemodynamic responses to salt, except for an increase in daytime heart rate. Urinary sodium excretion and lithium clearance were lower with pioglitazone, particularly with the LS diet (P < 0.05), suggesting increased sodium reabsorption at the proximal tubule. Pioglitazone significantly increased plasma renin activity with the LS (P = 0.02) and HS (P = 0.03) diets. Similar trends were observed with aldosterone. Atrial natriuretic levels did not change with pioglitazone. Body weight increased with pioglitazone in most subjects. Pioglitazone stimulates plasma renin activity and favors sodium retention and weight gain in healthy volunteers. These effects could contribute to the development of edema in some subjects treated with glitazones.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>15001599</pmid><doi>10.1210/jc.2003-031526</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-972X |
ispartof | The journal of clinical endocrinology and metabolism, 2004-03, Vol.89 (3), p.1140-1145 |
issn | 0021-972X 1945-7197 |
language | eng |
recordid | cdi_proquest_miscellaneous_71718739 |
source | Oxford Journals Online |
subjects | Adult Aldosterone - blood Atrial Natriuretic Factor - blood Biological and medical sciences Blood Pressure - drug effects Cross-Over Studies Diet, Sodium-Restricted Endocrinopathies Fundamental and applied biological sciences. Psychology Humans Hypoglycemic Agents - administration & dosage Male Medical sciences Placebos Receptors, Cytoplasmic and Nuclear - agonists Renal Circulation - drug effects Renin - blood Sodium Chloride - pharmacokinetics Sodium Chloride - urine Thiazolidinediones - administration & dosage Transcription Factors - agonists Vertebrates: endocrinology |
title | Effects of the Peroxisomal Proliferator-Activated Receptor-γ Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Healthy Men |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A18%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20the%20Peroxisomal%20Proliferator-Activated%20Receptor-%CE%B3%20Agonist%20Pioglitazone%20on%20Renal%20and%20Hormonal%20Responses%20to%20Salt%20in%20Healthy%20Men&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Zanchi,%20Anne&rft.date=2004-03&rft.volume=89&rft.issue=3&rft.spage=1140&rft.epage=1145&rft.pages=1140-1145&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2003-031526&rft_dat=%3Cproquest_cross%3E71718739%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4528-33590c3b998741be9413753f535583a774f82d7cbb6a27dd48fef611d694a7763%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71718739&rft_id=info:pmid/15001599&rfr_iscdi=true |